RT Journal Article
T1 Cost-Effective, Safe, and Personalized Cell Therapy for Critical Limb Ischemia in Type 2 Diabetes Mellitus.
A1 Soria-Juan, Bárbara
A1 Escacena, Natalia
A1 Capilla-González, Vivian
A1 Aguilera, Yolanda
A1 Llanos, Lucía
A1 Tejedo, Juan R
A1 Bedoya, Francisco J
A1 Juan, Verónica
A1 De la Cuesta, Antonio
A1 Ruiz-Salmerón, Rafael
A1 Andreu, Enrique
A1 Grochowicz, Lukas
A1 Prósper, Felipe
A1 Sánchez-Guijo, Fermín
A1 Lozano, Francisco S
A1 Miralles, Manuel
A1 Del Río-Solá, Lourdes
A1 Castellanos, Gregorio
A1 Moraleda, José M
A1 Sackstein, Robert
A1 García-Arranz, Mariano
A1 García-Olmo, Damián
A1 Martín, Franz
A1 Hmadcha, Abdelkrim
A1 Soria, Bernat
A1 Collaborative Working Group “Noma Project Team”, 
K1 cell-based therapy
K1 cellular medicaments
K1 clinical trials
K1 cost-effective
K1 critical limb ischemia
K1 diabetes
AB Cell therapy is a progressively growing field that is rapidly moving from preclinical model development to clinical application. Outcomes obtained from clinical trials reveal the therapeutic potential of stem cell-based therapy to deal with unmet medical treatment needs for several disorders with no therapeutic options. Among adult stem cells, mesenchymal stem cells (MSCs) are the leading cell type used in advanced therapies for the treatment of autoimmune, inflammatory and vascular diseases. To date, the safety and feasibility of autologous MSC-based therapy has been established; however, their indiscriminate use has resulted in mixed outcomes in preclinical and clinical studies. While MSCs derived from diverse tissues share common properties depending on the type of clinical application, they markedly differ within clinical trials in terms of efficacy, resulting in many unanswered questions regarding the application of MSCs. Additionally, our experience in clinical trials related to critical limb ischemia pathology (CLI) shows that the therapeutic efficacy of these cells in different animal models has only been partially reproduced in humans through clinical trials. Therefore, it is crucial to develop new research to identify pitfalls, to optimize procedures and to clarify the repair mechanisms used by these cells, as well as to be able to offer a next generation of stem cell that can be routinely used in a cost-effective and safe manner in stem cell-based therapies targeting CLI.
YR 2019
FD 2019-06-04
LK http://hdl.handle.net/10668/14162
UL http://hdl.handle.net/10668/14162
LA en
DS RISalud
RD Apr 8, 2025